Autres langues Mabpharm Limited

Actions

2181

KYG5780F1046

Recherche biotechnologique et médicale

Marché Fermé - Hong Kong S.E. 10:08:55 11/09/2026			Varia. 5j.	Varia. 1 janv.
0,4350 ^HKD	-3,33%		-2,25%	-13,00%

28/08	Mabpharm Limited publie ses résultats pour le semestre clos le 30 juin 2026	CI
24/06	Mabpharm Limited obtient l'approbation de sa demande de nouveau medicament pour le CMAB807X (Denosumab en injection)	CI

Autres langues

28/08	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026
24/06	Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection)
09/06	Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration
09/06	Mabpharm's Application for Osteoporosis Drug Approved in China
26/03	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2025
26/03	Mabpharm FY profit and total comprehensive income attributable rmb57.1 million
05/12	Mabpharm Limited Announces Change of Address of Principal Place of Business in Hong Kong
31/10/25	Mabpharm Limited Announces Board and Committee Changes, Effective October 31, 2025
28/08/25	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2025
27/03/25	Mabpharm Shrinks Loss by 39% in 2024
26/03/25	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2024
03/01/25	Mabpharm's Infliximab Drug Receives Approval from Pakistan's Drug Regulator
02/01/25	Mabpharm Limited Announces Approval from the Drug Regulatory Authority of Pakistan on the Registration of Core Product, CMAB008 (Infliximab for Injection)
27/12/24	Mabpharm Limited Announces Approval from the Indonesian National Agency of Drug and Food Control on the Marketing Authorization of its Core Product, CMAB008 (Infliximab for Injection)
28/08/24	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2024
10/07/24	Mabpharm Limited Announces Changes to Its Board
10/07/24	Mabpharm Limited Announces Resignation of Li Yunfeng as Chief Financial Officer
02/07/24	Mabpharm's New Drug Application Gets Peru's Regulator's Approval
02/07/24	Mabpharm Limited Announces Approval from the Ministry of Health of Peru on the New Drug Application of CMAB008 (Infliximab for Injection)
26/06/24	Simcere Zaiming and Mabpharm Limited Announce Approval of Cetuximab Beta in China by the NMPA
25/06/24	Simcere-Mabpharm Cancer Drug Gets Marketing Approval in China
25/06/24	Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China
25/06/24	Mabpharm Limited Announces Approval from the National Medical Products Administration of the People's Republic of China
26/03/24	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023
10/01/24	Livzon Pharma Recognizes Credit, Asset Impairments